Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing
- PMID: 3190503
- DOI: 10.1001/archneur.1988.00520350055016
Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing
Abstract
Some features of cerebellar ataxia have been reported to regress partially with long-term administration of 5-hydroxytryptophan or levorotatory form of 5-hydroxytryptophan. To test this effect further, 30 patients with various inherited or acquired cerebellar ataxias underwent a randomized, double-blind trial of placebo, and the levorotatory form of 5-hydroxytryptophan taken orally for four months. The levorotatory form of 5-hydroxytryptophan significantly improved the ataxia score. It also significantly modified the time of standing upright, the spread of feet, the speed of walking, speaking, and writing. In five cases in which the levorotatory form of 5-hydroxytryptophan therapy was maintained for 12 months, the effect continued progressively.
Comment in
-
Cerebellar ataxia.Arch Neurol. 1989 Nov;46(11):1166. doi: 10.1001/archneur.1989.00520470016011. Arch Neurol. 1989. PMID: 2818245 No abstract available.
-
Treatment of hereditary ataxia with the levorotatory form of hydroxytryptophan.Arch Neurol. 1995 May;52(5):440-1. doi: 10.1001/archneur.1995.00540290018003. Arch Neurol. 1995. PMID: 7733833 No abstract available.
Similar articles
-
Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases.Arch Neurol. 1995 May;52(5):451-5. doi: 10.1001/archneur.1995.00540290037015. Arch Neurol. 1995. PMID: 7733838 Clinical Trial.
-
Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia.Prog Brain Res. 1997;114:589-99. doi: 10.1016/s0079-6123(08)63389-0. Prog Brain Res. 1997. PMID: 9193169 Clinical Trial.
-
Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study.Arch Neurol. 1995 May;52(5):456-60. doi: 10.1001/archneur.1995.00540290042016. Arch Neurol. 1995. PMID: 7733839 Clinical Trial.
-
Pharmacological treatments of cerebellar ataxia.Cerebellum. 2004;3(2):107-11. doi: 10.1080/147342204100032331. Cerebellum. 2004. PMID: 15233578 Review.
-
Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.Cerebellum. 2016 Feb;15(1):38-42. doi: 10.1007/s12311-015-0733-1. Cerebellum. 2016. PMID: 26519380 Review.
Cited by
-
Is the promise of randomized control trials ("evidence-based medicine") overstated?Curr Neurol Neurosci Rep. 2002 Jan;2(1):1-8. doi: 10.1007/s11910-002-0044-z. Curr Neurol Neurosci Rep. 2002. PMID: 11898575 Review. No abstract available.
-
5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology.Int J Mol Sci. 2020 Dec 26;22(1):181. doi: 10.3390/ijms22010181. Int J Mol Sci. 2020. PMID: 33375373 Free PMC article. Review.
-
PK/PD modeling of 5-hydroxytryptophan (5-HTP) challenge test with cortisol measurement in serum and saliva.Pharmacol Res Perspect. 2020 Apr;8(2):e00574. doi: 10.1002/prp2.574. Pharmacol Res Perspect. 2020. PMID: 32168433 Free PMC article. Clinical Trial.
-
Continuous subcutaneous lisuride infusion in OPCA.J Neural Transm Gen Sect. 1992;90(2):145-50. doi: 10.1007/BF01250796. J Neural Transm Gen Sect. 1992. PMID: 1463593
-
Diverse Neuron Properties and Complex Network Dynamics in the Cerebellar Cortical Inhibitory Circuit.Front Mol Neurosci. 2019 Nov 7;12:267. doi: 10.3389/fnmol.2019.00267. eCollection 2019. Front Mol Neurosci. 2019. PMID: 31787879 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources